Asset

ITRACONAZOLE

Pulmatrix Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (2)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT03479411phase1completed2018-02-092018-06-28Pulmatrix Inc.Safety, Tolerability and Pharmacokinetics of PUR1900 (Itraconazole Powder) in Healthy Volunteers and Adults With Asthma
NCT05667662phase2terminated2023-02-012024-02-27Pulmatrix Inc.Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)